Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance

AbstractRecent developments of organoids engineering and organ-on-a-chip microfluidic technologies have enabled the recapitulation of the major functions and architectures of microscale human tissue, including tumor pathophysiology. Nevertheless, there remain challenges in recapitulating the complexity and heterogeneity of tumor microenvironment. The integration of these engineering technologies suggests a potential strategy to overcome the limitations in reconstituting the perfusable microvascular system of large-scale tumors conserving their key functional features. Here, we review the recent progress of in vitro tumor-on-a-chip microfluidic technologies, focusing on the reconstruction of microvascularized organoid models to suggest a better platform for personalized cancer medicine.

Download Full-text

Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine

Journal of Genetics and Genomics ◽

10.1016/j.jgg.2021.03.007 ◽

2021 ◽

Author(s):

Fangyoumin Feng ◽

Bihan Shen ◽

Xiaoqin Mou ◽

Yixue Li ◽

Hong Li

Keyword(s):

Large Scale ◽

Drug Response ◽

Response Prediction ◽

Personalized Cancer Medicine ◽

Cancer Medicine ◽

Personalized Cancer ◽

Pharmacogenomic Studies

Download Full-text

The Concept of Personalized Cancer Medicine with Natural Products

Planta Medica ◽

10.1055/s-0032-1307486 ◽

2012 ◽

Vol 78 (05) ◽

Cited By ~ 7

Author(s):

T Efferth

Keyword(s):

Natural Products ◽

Personalized Cancer Medicine ◽

Cancer Medicine ◽

Personalized Cancer

Download Full-text

Personalized Cancer Medicine in the Media: Sensationalism or Realistic Reporting?

Journal of Personalized Medicine ◽

10.3390/jpm11080741 ◽

2021 ◽

Vol 11 (8) ◽

pp. 741

Author(s):

Katherine Hicks-Courant ◽

Jenny Shen ◽

Angela Stroupe ◽

Angel Cronin ◽

Elizabeth F. Bair ◽

...

Keyword(s):

Personalized Medicine ◽

Media Coverage ◽

Disease Risk ◽

Federal Drug Administration ◽

Personalized Cancer Medicine ◽

The Media ◽

Cancer Medicine ◽

Media Reports ◽

Personalized Cancer ◽

Standard Tests

Background: Given that media coverage can shape healthcare expectations, it is essential that we understand how the media frames “personalized medicine” (PM) in oncology, and whether information about unproven technologies is widely disseminated. Methods: We conducted a content analysis of 396 news reports related to cancer and PM published between 1 January 1998 and 31 December 2011. Two coders independently coded all the reports using a pre-defined framework. Determination of coverage of “standard” and “non-standard” therapies and tests was made by comparing the media print/broadcast date to the date of Federal Drug Administration approval or incorporation into clinical guidelines. Results: Although the term “personalized medicine” appeared in all reports, it was clearly defined only 27% of the time. Stories more frequently reported PM benefits than challenges (96% vs. 48%, p < 0.001). Commonly reported benefits included improved treatment (89%), prediction of side effects (30%), disease risk prediction (33%), and lower cost (19%). Commonly reported challenges included high cost (28%), potential for discrimination (29%), and concerns over privacy and regulation (21%). Coverage of inherited DNA testing was more common than coverage of tumor testing (79% vs. 25%, p < 0.001). Media reports of standard tests and treatments were common; however, 8% included information about non-standard technologies, such as experimental medications and gene therapy. Conclusion: Confusion about personalized cancer medicine may be exacerbated by media reports that fail to clearly define the term. While most media stories reported on standard tests and treatments, an emphasis on the benefits of PM may lead to unrealistic expectations for cancer genomic care.

Download Full-text